Pathogenesis of calciphylaxis: Hans Selye to nuclear factor κ-B

Journal of the American Academy of Dermatology

Volumn 58, Issue 3, 2008, Pages 458-471

  Weenig, Roger H ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CALCIUM; CALCIUM PHOSPHATE; ENDOTHELIN 1; ESTROGEN; FETUIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEPTIN; MATRIX PROTEIN; OSTEOPROTEGERIN; PARATHYROID HORMONE; PHOSPHATE; TRANSCRIPTION FACTOR RUNX; TUMOR NECROSIS FACTOR;

BLOOD VESSEL CALCIFICATION; BLOOD VESSEL OCCLUSION; BONE MINERALIZATION; CALCINOSIS; CLINICAL FEATURE; HISTOPATHOLOGY; HUMAN; HYPERCALCEMIA; OSTEOLYSIS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN CALCIFICATION;

ANIMALS; BONE RESORPTION; CALCIFICATION, PHYSIOLOGIC; CALCIPHYLAXIS; CALCIUM; HISTORY, 20TH CENTURY; HUMANS; LIGANDS; NF-KAPPA B; PARATHYROID HORMONE; PHOSPHATES; RECEPTORS, CELL SURFACE; UNITED STATES; VASCULAR DISEASES;

EID: 39149113792     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2007.12.006     Document Type: Review

References (149)

1. Weenig R.H., Sewell L.D., Davis M.D., McCarthy J.T., and Pittelkow M.R. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56 (2007) 569-579
2. Selye H. Calciphylaxis (1962), University of Chicago Press, Chicago p. 1
3. In: Braun-Falco O., Plewig G., Wolff H.H., and Burgdorf W.H.C. (Eds). Dermatology. 2nd ed. (2000), Springer, Berlin 1328-1330
4. Fairley J.A. Calcifying and ossifying disorders of the skin. In: Bolognia J.L., Jorizzo J.L., and Rapini R.P. (Eds). Dermatology Vol 1 (2003), Mosby, London 692-694
5. Jono S., McKee M.D., Murry C.E., Shioi A., Nishizawa Y., Mori K., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87 (2000) E10-E17
6. Reynolds J.L., Joannides A.J., Skepper J.N., McNair R., Schurgers L.J., Proudfoot D., et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15 (2004) 2857-2867
7. Yang H., Curinga G., and Giachelli C.M. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 66 (2004) 2293-2299
8. London G.M., Guerin A.P., Marchais S.J., Metivier F., Pannier B., and Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18 (2003) 1731-1740
9. London G.M., Marty C., Marchais S.J., Guerin A.P., Metivier F., and de Vernejoul M.C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15 (2004) 1943-1951
10. Ishida M., Yao N., Yachiku S., Anzai T., Kobayashi T., and Ishida H. Management of calcium, phosphorus and bone metabolism in dialysis patients using sevelamer hydrochloride and vitamin D therapy. Ther Apher Dial 9 Suppl (2005) S16-S21
11. Tanko L.B., Bagger Y.Z., and Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 73 (2003) 15-20
12. Pennisi P., Signorelli S.S., Riccobene S., Celotta G., Di Pino L., La Malfa T., et al. Low bone density and abnormal bone turnover in patients with atherosclerosis of peripheral vessels. Osteoporos Int 15 (2004) 389-395
13. Samelson E.J., Kiel D.P., Broe K.E., Zhang Y., Cupples L.A., Hannan M.T., et al. Metacarpal cortical area and risk of coronary heart disease: the Framingham Study. Am J Epidemiol 159 (2004) 589-595
14. Schulz E., Arfai K., Liu X., Sayre J., and Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 89 (2004) 4246-4253
15. Ahmed S., O'Neill K.D., Hood A.F., Evan A.P., and Moe S.M. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 37 (2001) 1267-1276
16. Collin-Osdoby P., Rothe L., Anderson F., Nelson M., Maloney W., and Osdoby P. Receptor activator of NF-κB and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276 (2001) 20659-20672
17. Nikolovski J., Kim B.S., and Mooney D.J. Cyclic strain inhibits switching of smooth muscle cells to an osteoblast-like phenotype. FASEB J 17 (2003) 455-457
18. Kaden J.J., Bickelhaupt S., Grobholz R., Haase K.K., Sarikoc A., Kilic R., et al. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulate aortic valve calcification. J Mol Cell Cardiol 36 (2004) 57-66
19. Schoppet M., Al-Fakhri N., Franke F.E., Katz N., Barth P.J., Maisch B., et al. Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-κB ligand in Mönckeberg's sclerosis and atherosclerosis. J Clin Endocrinol Metab 89 (2004) 4104-4112
20. Tintut Y., Abedin M., Cho J., Choe A., Lim J., and Demer L.L. Regulation of RANKL-induced osteoclastic differentiation by vascular cells. J Mol Cell Cardiol 39 (2005) 389-393
21. Harada H., Tagashira S., Fujiwara M., Ogawa S., Katsumata T., Yamaguchi A., et al. Cbfa1 isoforms exert functional differences in osteoblast differentiation. J Biol Chem 274 (1999) 6972-6978
22. Geoffroy V., Kneissel M., Fournier B., Boyde A., and Matthias P. High bone resorption in adult aging transgenic mice overexpressing cbf1/runx2 in cells of the osteoblastic lineage. Mol Cell Biol 22 (2002) 6222-6233
23. Vidal N.O., Brandstrom H., Jonsson K.B., and Ohlsson C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol 159 (1998) 191-195
24. Hofbauer L.C., Gori F., Riggs B.L., Lacey D.L., Dunstan C.R., Spelsberg T.C., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140 (1999) 4382-4389
25. Sasaki N., Kusano E., Ando Y., Yano K., Tsuda E., and Asano Y. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. Nephrol Dial Transplant 16 (2001) 479-482
26. Hofbauer L.C., Shui C., Riggs B.L., Dunstan C.R., Spelsberg T.C., O'Brien T., et al. Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun 280 (2001) 334-339
27. Ma Y.L., Cain R.L., Halladay D.L., Yang X., Zeng Q., Miles R.R., et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology 142 (2001) 4047-4054
28. Coen G., Ballanti P., Balducci A., Calabria S., Fischer M.S., Jankovic L., et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 17 (2002) 233-238
29. Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Riggs B.L., and Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250 (1998) 776-781
30. Bezerra M.C., Calomeni G.D., Caparbo V.F., Gebrim E.S., Rocha M.S., and Pereira R.M. Low bone density and low serum levels of soluble RANK ligand are associated with severe arterial calcification in patients with Takayasu arteritis. Rheumatology (Oxford) 44 (2005) 1503-1506
31. Hofbauer L.C., Lacey D.L., Dunstan C.R., Spelsberg T.C., Riggs B.L., and Khosla S. Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25 (1999) 255-259
32. Ma T., Miyanishi K., Suen A., Epstein N.J., Tomita T., Smith R.L., et al. Human interleukin-1-induced murine osteoclastogenesis is dependent on RANKL, but independent of TNF-α. Cytokine 26 (2004) 138-144
33. Wei S., Kitaura H., Zhou P., Ross F.P., and Teitelbaum S.L. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 115 (2005) 282-290
34. Brandstrom H., Jonsson K.B., Vidal O., Ljunghall S., Ohlsson C., and Ljunggren O. Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 248 (1998) 454-457
35. Catrina A.I., af Klint E., Ernestam S., Catrina S.B., Makrygiannakis D., Botusan I.R., et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. Arthritis Rheum 54 (2006) 76-81
36. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., and Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 (1999) 4367-4370
37. Saika M., Inoue D., Kido S., and Matsumoto T. 17β-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α. Endocrinology 142 (2001) 2205-2212
38. Eghbali-Fatourechi G., Khosla S., Sanyal A., Boyle W.J., Lacey D.L., and Riggs B.L. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest 111 (2003) 1221-1230
39. Rzewuska-Lech E., Jayachandran M., Fitzpatrick L.A., and Miller V.M. Differential effects of 17β-estradiol and raloxifene on VSMC phenotype and expression of osteoblast-associated proteins. Am J Physiol Endocrinol Metab 289 (2005) E105-E112
40. Murakami T., Yamamoto M., Ono K., Nishikawa M., Nagata N., Motoyoshi K., et al. Transforming growth factor-β1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem Biophys Res Commun 252 (1988) 747-752
41. Price P.A., June H.H., Buckley J.R., and Williamson M.K. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21 (2001) 1610-1616
42. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19 (2004) 1059-1066
43. Viereck V., Emons G., Lauck V., Frosch K.H., Blaschke S., Grundker C., et al. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291 (2002) 680-686
44. Kobayashi A., Hirano F., and Makino I. The inhibitory effect of bisphosphonates on glucocorticoid-induced RANKL expression in human cells. Scand J Rheumatol 34 (2005) 480-484
45. Nishida S., Tsubaki M., Hoshino M., Namimatsu A., Uji H., Yoshioka S., et al. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Biochem Biophys Res Commun 328 (2005) 91-97
46. Sprague S.M., and Bushinsky D.A. Mechanism of aluminum-induced calcium efflux from cultured neonatal mouse calvariae. Am J Physiol 258 (1990) F583-F588
47. Zhang H., and Johnson P. Differential effects of aluminum ion on smooth muscle calpain I and calpain II activities. Int J Biochem 24 (1992) 1773-1778
48. Holloway W.R., Collier F.M., Aitken C.J., Malakellis M., Gough T.S., Myers D.E., et al. Leptin inhibits osteoclast generation. [abstract]. J Bone Miner Res 15 Suppl (2000) S174
49. Burguera B., Hofbauer L.C., Thomas T., Gori F., Evans G.L., Khosla S., et al. Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology 142 (2001) 3546-3553
50. Parhami F., Tintut Y., Ballard A., Fogelman A.M., and Demer L.L. Leptin enhances the calcification of vascular cells: artery wall as a target of leptin. Circ Res 88 (2001) 954-960
51. Lamghari M., Tavares L., Camboa N., and Barbosa M.A. Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts. J Cell Biochem 98 (2006) 1123-1129
52. Kim N., Odgren P.R., Kim D.K., Marks Jr. S.C., and Choi Y. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A 97 (2000) 10905-10910
53. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 97 (2000) 1566-1571
54. Aya K., Alhawagri M., Hagen-Stapleton A., Kitaura H., Kanagawa O., and Novack D.V. NF-κB-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 115 (2005) 1848-1854
55. Lomaga M.A., Yeh W.C., Sarosi I., Duncan G.S., Furlonger C., Ho A., et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13 (1999) 1015-1024
56. Doffinger R., Smahi A., Bessia C., Geissmann F., Feinberg J., Durandy A., et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nat Genet 27 (2001) 277-285
57. Iotsova V., Caamano J., Loy J., Yang Y., Lewin A., and Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 3 (1997) 1285-1289
58. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
59. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
60. Arko B., Prezelj J., Komel R., Kocijancic A., Hudler P., and Marc J. Sequence variations in the osteoprotegerin gene promoter in patients with postmenopausal osteoporosis. J Clin Endocrinol Metab 87 (2002) 4080-4084
61. Brändström H., Stiger F., Lind L., Kahan T., Melhus H., and Kindmark A. A single nucleotide polymorphism in the promoter region of the human gene for osteoprotegerin is related to vascular morphology and function. Biochem Biophys Res Commun 293 (2002) 13-17
62. Brändström H., Stiger F., Kahan T., Melhus H., Nyström F., Öhman K.P., et al. A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients: the Swedish irbesartan left ventricular hypertrophy investigation vs atenolol (SILVHIA). Blood Press 13 (2004) 152-157
63. Soufi M., Schoppet M., Sattler A.M., Herzum M., Maisch B., Hofbauer L.C., et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab 89 (2004) 3764-3768
64. Arko B., Prezelj J., Kocijancic A., Komel R., and Marc J. Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women. Maturitas 51 (2005) 270-279
65. Choi J.Y., Shin A., Park S.K., Chung H.W., Cho S.I., Shin C.S., et al. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women. Calcif Tissue Int 77 (2005) 152-159
66. Price P.A., Omid N., Than T.N., and Williamson M.K. The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71 (2002) 356-363
67. Monney P., Nguyen Q.V., Perroud H., and Descombes E. Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure. Nephrol Dial Transplant 19 (2004) 2130-2132
68. Shiraishi N., Kitamura K., Miyoshi T., Adachi M., Kohda Y., Nonoguchi H., et al. Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium. Am J Kidney Dis 48 (2006) 151-154
69. Ghosh S., Cowen S., Hannan W.J., and Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 107 (1994) 1031-1039
70. Gokhale R., Favus M.J., Karrison T., Sutton M.M., Rich B., and Kirschner B.S. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 114 (1998) 902-911
71. Stompor T., Pasowicz M., Sullowicz W., Dembinska-Kiec A., Janda K., Wojcik K., et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 41 (2003) 203-211
72. Skoumal M., Kolarz G., Haberhauer G., Woloszczuk W., Hawa G., and Klingler A. Osteoprotegerin and the receptor activator of NF-κB ligand in the serum and synovial fluid: a comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 26 (2005) 63-69
73. Pettit A.R., Walsh N.C., Manning C., Goldring S.R., and Gravallese E.M. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 45 (2006) 1068-1076
74. Tanaka K., Inaba M., Goto H., Nagata-Sakurai M., Sakai S., Yamada S., et al. Paraarticular trabecular bone loss at the ultradistal radius and increased arterial stiffening in postmenopausal patients with rheumatoid arthritis. J Rheumatol 33 (2006) 652-658
75. Tintut Y., Patel J., Parhami F., and Demer L.L. Tumor necrosis factor-α promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation 102 (2000) 2636-2642
76. Shioi A., Katagi M., Okuno Y., Mori K., Jono S., Koyama H., et al. Induction of bone-type alkaline phosphatase in human vascular smooth muscle cells: roles of tumor necrosis factor-α and oncostatin M derived from macrophages. Circ Res 91 (2002) 9-16
77. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., and Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95 (1995) 2409-2415
78. Khoruts A., Stahnke L., McClain C.J., Logan G., and Allen J.I. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 13 (1991) 267-276
79. Komori T., Yagi H., Nomura S., Yamaguchi A., Sasaki K., Deguchi K., et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89 (1997) 755-764
80. Ducy P., Starbuck M., Priemel M., Shen J., Pinero G., Geoffroy V., et al. A Cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. Genes Dev 13 (1999) 1025-1036
81. Engelse M.A., Neele J.M., Bronckers A.L., Pannekoek H., and de Vries C.J. Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor α-1 and the protective factor matrix Gla protein in human atherogenesis. Cardiovasc Res 52 (2001) 281-289
82. Steitz S.A., Speer M.Y., Curinga G., Yang H.Y., Haynes P., Aebersold R., et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89 (2001) 1147-1154
83. Faugere M.C., Arnala I.O., Ritz E., and Malluche H.H. Loss of bone resulting from accumulation of aluminum in bone of patients undergoing dialysis. J Lab Clin Med 107 (1986) 481-487
84. Smith A.J., Faugere M.C., Abreo K., Fanti P., Julian B., and Malluche H.H. Aluminum-related bone disease in mild and advanced renal failure: evidence for high prevalence and morbidity and studies on etiology and diagnosis. Am J Nephrol 6 (1986) 275-283
85. Sedman A.B., Alfrey A.C., Miller N.L., and Goodman W.G. Tissue and cellular basis for impaired bone formation in aluminum-related osteomalacia in the pig. J Clin Invest 79 (1987) 86-92
86. Kasai K., Hori M.T., and Goodman W.G. Transferrin enhances the antiproliferative effect of aluminum on osteoblast-like cells. Am J Physiol 260 (1991) E537-E543
87. Mawad H.W., Sawaya B.P., Sarin R., and Malluche H.H. Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 52 (1999) 160-166
88. Hak A.E., Pols H.A., van Hemert A.M., Hofman A., and Witteman J.C. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol 20 (2000) 1926-1931
89. Bakhireva L.N., Barrett-Connor E.L., Laughlin G.A., and Kritz-Silverstein D. Differences in association of bone mineral density with coronary artery calcification in men and women: the Rancho Bernardo study. Menopause 12 (2005) 691-698
90. Nordfors L., Lonnqvist F., Heimburger O., Danielsson A., Schalling M., and Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int 54 (1998) 1267-1275
91. Shamsuzzaman A.S., Winnicki M., Wolk R., Svatikova A., Phillips B.G., Davison D.E., et al. Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation 109 (2004) 2181-2185
92. Hall S.W., Luna M.A., Bedrossian C., and Rodriquez V. Calcinosis in nonparathyroid malignant disease: an unusual case report and clinicopathologic review of 17 cases. Med Pediatr Oncol 4 (1978) 49-58
93. Mine Y., Ito N., Tagawa M., Imamura K., Mori I., Kitamura T., et al. Metastatic calcification associated with malignancy. [in Japanese]. Gan No Rinsho 34 (1988) 2044-2051
94. Mastruserio D.N., Nguyen E.Q., Nielsen T., Hessel A., and Pellegrini A.E. Calciphylaxis associated with metastatic breast carcinoma. J Am Acad Dermatol 41 (1999) 295-298
95. Kutlu N.O., Aydin N.E., Aslan M., Bulut T., and Ozgen U. Malignant melanoma of the soft parts showing calciphylaxis. Pediatr Hematol Oncol 20 (2003) 141-146
96. De Roma I., Filotico R., Cea M., Procaccio P., and Perosa F. Calciphylaxis in a patient with POEMS syndrome without renal failure and/or hyperparathyroidism: a case report. Ann Ital Med Int 19 (2004) 283-287
97. Kitazawa S., and Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198 (2002) 228-236
98. Roux S., and Mariette X. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-κB) and RANK ligand expression. Leuk Lymphoma 45 (2004) 1111-1118
99. Benit A., Allard J., Rimailho J., Fauvel J., Escourrou G., Vezzosi D., et al. Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels. J Endocrinol Invest 29 (2006) 443-449
100. Chen G., Sircar K., Aprikian A., Potti A., Goltzman D., and Rabbani S.A. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107 (2006) 289-298
101. Gupta R., and Neal J.M. Hypercalcemia due to vitamin D-secreting Hodgkin's lymphoma exacerbated by oral calcium supplementation. Endocr Pract 12 (2006) 227-229
102. Lau Y.S., Sabokbar A., Giele H., Cerundolo V., Hofstetter W., and Athanasou N.A. Malignant melanoma and bone resorption. Br J Cancer 94 (2006) 1496-1503
103. Matsumoto T., and Abe M. Bone destruction in multiple myeloma. Ann N Y Acad Sci 1068 (2006) 319-326
104. Niizuma H., Fujii K., Sato A., Fujiwara I., Takeyama J., and Imaizumi M. PTHrP-independent hypercalcemia with increased proinflammatory cytokines and bone resorption in two children with CD19-negative precursor B acute lymphoblastic leukemia. Pediatr Blood Cancer 49 (2007) 990-993
105. Weiss E.S., Doty J., Brock M.V., Halvorson L., and Yang S.C. A case of ectopic parathyroid hormone production by a pulmonary neoplasm. J Thorac Cardiovasc Surg 131 (2006) 923-924
106. Woods M., Wood E.G., Mitchell J.A., and Warner T.D. Signal transduction pathways involved in cytokine stimulation of endothelin-1 release from human vascular smooth muscle cells. J Cardiovasc Pharmacol 36 Suppl (2000) S407-S409
107. Wu S.Y., Zhang B.H., Pan C.S., Jiang H.F., Pang Y.Z., Tang C.S., et al. Endothelin-1 is a potent regulator in vivo in vascular calcification and in vitro in calcification of vascular smooth muscle cells. Peptides 24 (2003) 1149-1156
108. Liakopoulos V., Wurth P., Mertens P.R., Eleftheriadis T., Kourti P., Voliotis G., et al. Endothelin-1 plasma levels in hemodialysis treatment: the influence of type 2 diabetes. Ren Fail 27 (2005) 515-522
109. Wozney J.M., Rosen V., Celeste A.J., Mitsock L.M., Whitters M.J., Kriz R.W., et al. Novel regulators of bone formation: molecular clones and activities. Science 242 (1988) 1528-1534
110. Cheng H., Jiang W., Phillips F.M., Haydon R.C., Peng Y., Zhou L., et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). [erratum appears in J Bone Joint Surg Am 2004;86-A:141]. J Bone Joint Surg Am 85-A (2003) 1544-1552
111. Davies M.R., Lund R.J., and Hruska K.A. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J Am Soc Nephrol 14 (2003) 1559-1567
112. Feng J.Q., Xing L., Zhang J.H., Zhao M., Horn D., Chan J., et al. NF-κB specifically activates BMP-2 gene expression in growth plate chondrocytes in vivo and in a chondrocyte cell line in vitro. J Biol Chem 278 (2003) 29130-29135
113. 2, and high intravascular pressure. Circulation 111 (2005) 2364-2372
114. Zebboudj A.F., Imura M., and Bostrom K. Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2. J Biol Chem 277 (2002) 4388-4394
115. Zebboudj A.F., Shin V., and Bostrom K. Matrix GLA protein and BMP-2 regulate osteoinduction in calcifying vascular cells. J Cell Biochem 90 (2003) 756-765
116. Luo G., Ducy P., McKee M.D., Pinero G.J., Loyer E., Behringer R.R., et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386 (1997) 78-81
117. Jono S., Ikari Y., Vermeer C., Dissel P., Hasegawa K., Shioi A., et al. Matrix Gla protein is associated with coronary artery calcification as assessed by electron-beam computed tomography. Thromb Haemost 91 (2004) 790-794
118. Price P.A., Faus S.A., and Williamson M.K. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol 20 (2000) 317-327
119. Brancaccio D., Biondi M.L., Gallieni M., Turri O., Galassi A., Cecchini F., et al. Matrix GLA protein gene polymorphisms: clinical correlates and cardiovascular mortality in chronic kidney disease patients. Am J Nephrol 25 (2005) 548-552
120. 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112 (2003) 357-366
121. Ketteler M., Bongartz P., Westenfeld R., Wildberger J.E., Mahnken A.H., Bohm R., et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361 (2003) 827-833
122. Chen N.X., O'Neill K.D., Duan D., and Moe S.M. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 62 (2002) 1724-1731
123. Moe S.M., O'Neill K.D., Duan D., Ahmed S., Chen N.X., Leapman S.B., et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61 (2002) 638-647
124. Chen N.X., Duan D., O'Neill K.D., Wolisi G.O., Koczman J.J., Laclair R., et al. The mechanisms of uremic serum-induced expression of bone matrix proteins in bovine vascular smooth muscle cells. Kidney Int 70 (2006) 1046-1053
125. Virchow R. Gesammelte Abhandlungen zur wissenschaflichen Medicin. Thrombose und Embolie. Gefässentzündung und septische Infection (1856), Verlag Von Meidinger R Sohn and Comp, Frankfurt am main pp. 219-732
126. Szotowski B., Antoniak S., Poller W., Schultheiss H.P., and Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res 96 (2005) 1233-1239
127. Fukudome K., and Esmon C.T. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 269 (1994) 26486-26491
128. Conway E.M., and Rosenberg R.D. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 8 (1988) 5588-5592
129. Klein N.J., Shennan G.I., Heyderman R.S., and Levin M. Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. J Cell Sci 102 (1992) 821-832
130. Mehta R.L., Scott G., Sloand J.A., and Francis C.W. Skin necrosis associated with acquired protein C deficiency in patients with renal failure and calciphylaxis. Am J Med 88 (1990) 252-257
131. Rostaing L., el Feki S., Delisle M.B., Durand-Malgouyres C., Ton-That H., Bonate J.L., et al. Calciphylaxis in a chronic hemodialysis patient with protein S deficiency. Am J Nephrol 5 (1995) 524-527
132. Korkmaz C., Dundar E., and Zubaroglu I. Calciphylaxis in a patient with rheumatoid arthritis without renal failure and hyperparathyroidism: the possible role of long-term steroid use and protein S deficiency. Clin Rheumatol 21 (2002) 66-69
133. Sewell L.D., Weenig R.H., Davis M.D., McEvoy M.T., and Pittelkow M.R. Low-dose tissue plasminogen activator for calciphylaxis. Arch Dermatol 140 (2004) 1045-1048
134. Vassa N., Twardowski Z.J., and Campbell J. Hyperbaric oxygen therapy in calciphylaxis-induced skin necrosis in a peritoneal dialysis patient. Am J Kidney Dis 23 (1994) 878-881
135. Podymow T., Wherrett C., and Burns K.D. Hyperbaric oxygen in the treatment of calciphylaxis: a case series. Nephrol Dial Transplant 16 (2001) 2176-2180
136. Basile C., Montanaro A., Masi M., Pati G., De Maio P., and Gismondi A. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol 15 (2002) 676-680
137. Dwyer K.M., Francis D.M., Hill P.A., and Murphy B.F. Calcific uremic arteriolopathy: local treatment and hyperbaric oxygen therapy. Nephrol Dial Transplant 17 (2002) 1148-1149
138. Yamami N., Shimaya K., Sera A.M., Fujita H., Shibayama M., Mano Y., et al. Alterations of fibrinolytic activity in human during and after hyperbaric oxygen exposure. Appl Human Sci 15 (1996) 239-242
139. Tjarnstrom J., Holmdahl L., Arnell P., Falkenberg M., and Risberg B. Treatment with hyperbaric oxygen affects endothelial cell fibrinolysis. Eur J Surg 165 (1999) 834-838
140. Tjarnstrom J., Holmdahl L., Falk P., Falkenberg M., Arnell P., and Risberg B. Effects of hyperbaric oxygen on expression of fibrinolytic factors of human endothelium in a simulated ischemia/reperfusion situation. Scand J Clin Lab Invest 61 (2001) 539-545
141. Russell R., Brookshire M.A., Zekonis M., and Moe S.M. Distal calcific uremic arteriolopathy in a hemodialysis patient responds to lowering of Ca × P product and aggressive wound care. Clin Nephrol 58 (2002) 238-243
142. Arch-Ferrer J.E., Beenken S.W., Rue L.W., Bland K.I., and Diethelm A.G. Therapy for calciphylaxis: an outcome analysis. Surgery 134 (2003) 941-944
143. Cicone J.S., Petronis J.B., Embert C.D., and Spector D.A. Successful treatment of calciphylaxis with intravenous sodium thiosulfate. Am J Kidney Dis 43 (2004) 1104-1108
144. Duffy A., Schurr M., Warner T., and Chen H. Long-term outcomes in patients with calciphylaxis from hyperparathyroidism. Ann Surg Oncol 13 (2006) 96-102
145. Velasco N., MacGregor M.S., Innes A., and MacKay I.G. Successful treatment of calciphylaxis with cinacalcet: an alternative to parathyroidectomy?. Nephrol Dial Transplant 21 (2006) 1999-2004
146. Dorai H., Vukicevic S., and Sampath T.K. Bone morphogenetic protein-7 (osteogenic protein-1) inhibits smooth muscle cell proliferation and stimulates the expression of markers that are characteristic of SMC phenotype in vitro. J Cell Physiol 184 (2000) 37-45
147. Min H., Morony S., Sarosi I., Dunstan C.R., Capparelli C., Scully S., et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 192 (2000) 463-474
148. Body J.J., Facon T., Coleman R.E., Lipton A., Geurs F., Fan M., et al. A study of the biological receptor activator of nuclear factor-κB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12 (2006) 1221-1228
149. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006) 821-831